Hepatitis C Treatment with First-Generation Protease Inhibitors in A Real-World Cohort- Risk-Benefit Profile and Costs of the Therapy
Abstract
Authors
I Cacciola C Giardina V Sirna R Macrì A D'Ausilio A Aiello E Latorre M Toumi R Filomia G Raimondo V Arcoraci AP Caputi